Biotechnology company Amylin said Tuesday it has asked the FDA to approve a once a week a treatment, a drug that’s based on its twice-daily injectable drug Byetta.
The advance is significant because right now most diabetics must take some kind of medication daily. The new strategy may substiantially change the way patients manage the disease.
According to CNBC Pharmaceutical Reporter Mike Huckman, if approved the drug could bring in a billion dollars a year in sales.
And he says most analysts weren't expecting this development for another month. “An earlier-than-anticipated filing might mean the timeline for potential agency approval of the drug also gets moved up. Most seem to think a decision could come early next year.”
The drug's competition would likely include Novo Nordisk's once-daily injection liraglutide, which is currently under FDA review
The U.S. market for diabetes drugs is currently worth about $5 billion per year.
> Click here for more from Mike Huckman’s blog, Pharma’s Market
Got something to to say? Send us an e-mail at email@example.com and your comment might be posted on the Rapid Recap. If you'd prefer to make a comment but not have it published on our website send your e-mail to firstname.lastname@example.org.
Trader disclosure: On May 5th, 2009, the following stocks and commodities mentioned or intended to be mentioned on CNBC’s Fast Money were owned by the Fast Money traders; Macke Owns (AAPL), (PCLN), (LVS), (SDS), (GE), (NFLX), (IMAX), (GS); Adami Owns (AGU), (C), (GS), (INTC), (MSFT), (NUE), (BTU); Seymour Owns (AAPL), (BAC), (BX), (RIO), (SBUX); Najarian Owns (BX) Call Spread; Najarian Owns (DFS) Calls; Najarian Owns (ERTS) Calls; Najarian Owns (FIG); Najarian Owns (MCD) And Is Short (MCD) Calls; Najarian Owns (MS) And Is Short (MS) Calls; Najarian Owns (PALM) And Is Short (PALM) Calls; Najarian Owns (XLI) Call Spread; Najarian Owns (XHB) Call Spread
GE Is The Parent Company Of CNBC
NBC Universal Is The Parent Company Of CNBC
Charles Schwab Is A Sponsor Of "Fast Money"